1678-P: B6-Alms1-del Mice, a Metabolic Syndrome Animal Model, Shows Semaglutide Benefits on Obesity, Hyperglycemia, and NAFL

Metabolic syndrome is a cluster of conditions that occur together, increasing the risk of heart disease, stroke and type 2 diabetes. These conditions include obesity, hyperglycemia, hypertension, hyperlipidemia. Leptin and leptin receptor mutant mice, ob/ob and db/db, are two classic metabolic syndrome animal model. However, the transient hyperglycemia of ob/ob and severe hyperglycemia induced premature death of db/db limit the application of these two models. To fill the gap, GemPharmatech developed a metabolic disorder model based on the mutation of Alms1 gene in mice (B6-Alms1-del mice). B6-Alms1-del mice gradually developed obesity from 8 weeks old with chow diet, accompanied by hyperglycemia, glucose and insulin intolerance, dyslipidemia and impaired liver function. Moreover, B6-Alms1-del mice developed severe non alcoholic fatty liver spontaneously as early as 21 weeks old and no premature death was observed around 5~8 months of ages. As B6-Alms1-del mice copied major features of metabolic syndrome, we further tested whether B6-Alms1-del mice could response to the positive drug semaglutide, an agonist of GLP-1R. 16 weeks old B6-Alms1-del mice were treated with vehicle and semaglutide for 5 weeks, respectively. Our results indicate that semaglutide lead to benefit on metabolic syndrome, including body weight control, improvement in hyperglycemia, hyperlipidemia, liver injury and hepatic steatosis. In conclusion, we have established a metabolic syndrome animal model that develop clinically relevant metabolic phenotypes and overcome the limitation of ob/ob and db/db. Furthermore, B6-Alms1-del mice responds to the approval anti-obesity drug semaglutide, which provide a useful model to assess the efficacy of novel metabolic syndrome therapies. Disclosure Z.Chen: None. M.Gao: None. X.Zhao: None. Z.Li: None. J.Zhao: None. C.Ju: None. X.Gao: None.